BioTrove, Inc. Licenses Genomics Application from Stanford University for Nanotiter Plates

Additional patent issued for cell-based assays strengthens

BioTrove's intellectual property portfolio

Jul 15, 2004, 01:00 ET from BioTrove, Inc.

    WOBURN, Mass., July 15 /PRNewswire/ -- BioTrove, Inc. announced today that
 the Company has acquired an exclusive license from Stanford University for
 patent applications that cover the use of a through-hole structured microarray
 to perform PCR.  Separately, BioTrove has been issued a patent on a novel
 method using the Company's proprietary OpenArray(TM) platform for high-density
 cell assay and culture.  BioTrove is commercializing its OpenArray(TM)
 platform, a nanofluidic system for massively parallel analysis using Thru-
 Hole(TM) technology, for use by life science researchers.
     "The Stanford patent applications and the cell maintenance patent are
 important parts of our large and growing patent portfolio around BioTrove's
 Thru-Hole(TM) technology," remarked Robert Hess, Director of Licensing and
 Intellectual Property at BioTrove.  "We identified these patent applications
 as potentially valuable because the inventors, Matthew O'Keefe and Pamela
 Foreman, were early to see the utility of performing high-density, parallel
 gene amplification in a through-hole structure."  The new BioTrove patent
 covers an innovative application of BioTrove's OpenArray(TM) technology that
 allows for the maintenance and growth of cells in a microfluidic environment,
 with potential application in cell-based assays.
     Both the licensing and the new patent strengthen BioTrove's existing
 through-hole array patent portfolio.  BioTrove's through-hole intellectual
 property portfolio includes eight patents issued or allowed and numerous
 patents pending.
     The OpenArray(TM) platform includes a nanotiter plate requiring only
 nanoliter-sized quantities of sample per through-hole.  It can be used for
 massively parallel and low-volume analysis of genetic, genomic, proteomic,
 biochemical and cellular samples.  The platform uniquely combines the
 parallelism of microarrays with the data quality of PCR to perform genetic and
 genomic assays, including genotyping and RNA expression analysis.
     About BioTrove, Inc.
     BioTrove, Inc. is a biotechnology company focused on advancing life
 science and drug discovery research by leveraging revolutionary micro- and
 nano-scale technologies.  BioTrove has two core platforms:  OpenArray(TM)
 Applications based on Thru-Hole(TM) technology, a broadly applicable nano-
 liter fluidics technology platform for massively parallel and low-volume
 analysis of genetic, genomic, proteomic, biochemical and cellular samples, and
 RapidFire(TM) Lead Discovery, an assay development and high throughput
 screening service that unlocks the value of intractable drug targets.  For
 more information on BioTrove, please visit the company's website at
     For information contact:
      Patrick T. Carroll
      BioTrove, Inc.
      Jennifer Cosenza
      Feinstein Kean Healthcare

SOURCE BioTrove, Inc.